Baxter International Inc. ($BAX) Stock Forecast: Up 5.2% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) is a global healthcare company that specializes in medical devices, pharmaceuticals, and biotechnology products. A strong bullish movement was observed in BAX stock today.

Why is Baxter International Inc. going up?

BAX stock is up 5.2% on Jan 15, 2026 15:21

• Baxter International Inc. introduced its Dynamo Series smart stretcher, emphasizing technological innovation in acute care to improve patient safety and hospital workflow efficiency, likely boosting the positive stock movement.
• Despite a decrease in stake by Manning & Napier Advisors LLC, growing interest from other institutional investors and Baxter's focus on connected care solutions may have bolstered market confidence and contributed to the bullish trend.
• Initially trailing behind competitors, Baxter International Inc.'s stock performance saw a shift towards optimism with the launch of the Dynamo Series smart stretcher, influencing the bullish market movement.
• FDA clearance for Medtronic's smart insulin pen app, though unrelated to Baxter, indicates progress in healthcare technology, potentially benefiting companies like Baxter International Inc. through positive market effects.

BAX Price Chart

BAX Technical Analysis

BAX News

Baxter Unveils Dynamo Smart Stretcher to Improve Hospital Safety

Baxter International Inc. is launching its Dynamo Series smart stretcher in the U.S., enhancing its connected care solutions for hospitals. This new stretcher aims to improve patient safety, comfort, and workflow efficiency by reducing unnecessary transfers and integrating advanced fall prevention technologies. The launch reinforces Baxter's focus on technological innovation in acute care, addressing clinical needs and supporting its Care & Connectivity segment, with the smart hospital beds market projected to grow significantly.

https://www.theglobeandmail.com/investing/markets/stocks/BAX/pressreleases/37043941/baxter-unveils-dynamo-smart-stretcher-to-improve-hospital-safety/

Manning & Napier Advisors LLC Sells 51,029 Shares of Baxter International Inc. $BAX

Manning & Napier Advisors LLC has reduced its stake in Baxter International Inc. (NYSE:BAX) by 11.2%, selling 51,029 shares and holding 404,514 shares valued at $9.21 million. Despite some institutional investors increasing their positions, analysts maintain a "Hold" consensus with an average target of $21.30, following recent price target cuts from UBS and Barclays. Baxter recently lowered its quarterly dividend to $0.01 per share.

https://www.marketbeat.com/instant-alerts/filing-manning-napier-advisors-llc-sells-51029-shares-of-baxter-international-inc-bax-2026-01-14/

Baxter International Inc. Stock Underperforms Tuesday When Compared To Competitors

Baxter International Inc. stock underperformed on Tuesday compared to its competitors. This article also details that Unity Software reported strong fourth-quarter financial results with revenue increasing 35% year-over-year to $609 million, surpassing the consensus estimate. However, Unity also reported a quarterly loss of 66 cents per share.

https://news.futunn.com/en/post/67347906/baxter-international-inc-stock-underperforms-tuesday-when-compared-to-competitors

Medtronic gets FDA clearance for smart insulin pen app

Medtronic has received FDA 510(k) clearance for its MiniMed Go app, which connects its smart insulin pens with Abbott's continuous glucose monitoring sensors. The app aims to improve glycemic control by providing dose calculators, missed dose alerts, and software reporting for healthcare providers. This development is part of a 2024 partnership between Medtronic and Abbott, offering an accessible solution for individuals who prefer insulin pens over pumps.

https://www.medtechdive.com/news/medtronic-clearance-insulin-pen-app-abbott/809479/

Baxter Introduces the Dynamo Series, a New Smart Stretcher to Help Address Common Challenges in Hospital Settings

Baxter International Inc. has unveiled the Dynamo Series smart stretcher, designed to address common challenges in hospital settings by easing the physical and cognitive burden on care teams and improving patient experience. This new stretcher, intended for use in emergency departments, perioperative environments, and patient transport, aims to minimize patient transfers, prevent falls through advanced technologies like SafeView+, and enhance patient safety and comfort with features like a wider care surface and one-touch positioning. The Dynamo Series is set for U.S. launch in the first half of 2026 and represents Baxter's latest innovation in smart beds and connected care.

https://www.rutlandherald.com/news/business/baxter-introduces-the-dynamo-series-a-new-smart-stretcher-to-help-address-common-challenges-in/article_f57e29c7-e4a3-5177-a983-78df5157b1f6.html

Trending Today

Ziliqa ($ZIL) Crypto Forecast: Up 78.2% Today

Copper ($COPPER) Commodity Forecast: Up 5.1% Today

Gold ($XAU) Commodity Forecast: Up 5.6% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.2% Today

Stox ($STX) Crypto Forecast: Up 16.7% Today

Ethereum ($ETH) Crypto Forecast: Up 5.8% Today

Silver ($XAG) Commodity Forecast: Up 5.9% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 6.3% Today

Hasbro Inc. ($HAS) Stock Forecast: Up 5.0% Today

Baxter International Inc. Price History

31.06.2025 - BAX Stock was down 21.0%

• Baxter International Inc. (BAX) experienced a significant bearish movement following its Q2 earnings report, where it missed both earnings and sales expectations.
• The company also revised its full-year EPS outlook downwards, leading to a lack of confidence among investors and a sharp decline in the stock price.
• The weaker gross margin reported by Baxter further added to the negative sentiment, causing shares to slide nearly 9% pre-market.
• The disappointing earnings results and lowered guidance suggest that Baxter may be facing challenges in its core segments, impacting investor perception and leading to the bearish market movement.

31.06.2025 - BAX Stock was down 19.7%

• The bearish movement in Baxter's stock today could be attributed to the market's reaction to the upcoming Q2 earnings report.
• Investors might be concerned about Baxter's ability to meet Wall Street's expectations for key metrics and deliver another solid quarter.
• The uncertainty surrounding the company's core segments' performance and the pressure to achieve modest growth could have contributed to the negative sentiment in the market.
• Traders might be reacting to the possibility of margin gains stabilizing after a recent recovery, which could impact Baxter's overall financial outlook and future growth prospects.

30.09.2025 - BAX Stock was down 14.2%

• There was a downward revision in Baxter International Inc.'s 2025 guidance, resulting in a notable decline in its stock value to a 52-week low.
• Despite exceeding expectations in its third-quarter earnings report, the company's reduced sales and EPS projections for 2025 influenced the negative market sentiment.
• Legal inquiries from Faruqi & Faruqi, LLP and a securities fraud class action lawsuit caution from Bernstein Liebhard LLP potentially heightened investor worries and further impacted the stock's performance.
• The stock faced a bearish trend following the mixed reactions to Baxter's Q3 earnings, which included surpassing earnings but missing sales targets, along with a downward adjustment in its 2025 EPS guidance.

30.09.2025 - BAX Stock was down 17.0%

• A looming deadline for a securities fraud class action lawsuit could have caused unease among investors, triggering a selloff of Baxter International Inc. shares.
• Weaknesses in the IV fluid and anesthesia segments, noted in the Q3 preview, may have raised concerns about the company's future revenue and earnings performance.
• Ongoing shareholder litigations and legal investigations might have heightened the negative sentiment surrounding Baxter International Inc., exerting downward pressure on its stock value.
• In sum, the intertwining factors of legal uncertainties, segment vulnerabilities, and shareholder disputes likely contributed to the bearish market movement witnessed in Baxter International Inc. today.

30.09.2025 - BAX Stock was down 14.8%

• Baxter International Inc. (BAX) surpassed Q3 earnings expectations but missed sales targets, prompting a downward revision of their 2025 EPS guidance.
• Despite positive performances in Pharma and Advanced Surgery, concerns arose among investors due to the overall sales miss and reduced EPS outlook, leading to a bearish market movement.
• The presence of an upcoming securities fraud class action lawsuit deadline and investor alerts may have further fueled negative sentiments around the company, impacting the stock price negatively.
• Investors are focusing on Baxter's core segments, notably Advanced Surgery and Drug Compounding, in the next quarter to evaluate the company's growth prospects in light of challenges faced by other product lines like IV fluids and anesthesia.

08.04.2025 - BAX Stock was up 5.3%

• The decline in short interest suggests growing investor confidence in Baxter Intl's future outlook.
• The positive market sentiment might be influenced by recent progress in healthcare, including treatment advancements and successful clinical trials.
• Investors could also be responding favorably to Baxter Intl's financial performance and strategic moves aimed at fostering growth.
• In summary, today's bullish movement in Baxter Intl's stock seems to stem from both reduced short interest and positive industry trends.

20.01.2025 - BAX Stock was up 8.9%

• Baxter's strong bullish movement today can be attributed to the better-than-expected Q4 adjusted EPS results, which exceeded both consensus estimates and the company's own guidance. This positive earnings report indicates that the company is performing well and has a solid financial outlook.
• The optimistic forecast for 2025 sales growth and adjusted EPS further boosted investor confidence in Baxter's future prospects, leading to increased buying interest in the stock.
• Despite the Q1 2025 EPS being projected below analyst estimates, the overall positive sentiment surrounding Baxter's performance and outlook likely overshadowed this minor concern, driving the stock price higher.
• Overall, Baxter's impressive financial results and optimistic guidance have propelled the stock to a bullish trajectory, reflecting investor optimism and confidence in the company's growth potential.

02.04.2025 - BAX Stock was down 5.0%

• Baxter exceeded sales expectations for medical devices in Q1, surpassing both internal projections and analyst forecasts.
• The optimistic guidance for 2025 should have instilled confidence in the company's future growth trajectory.
• Market volatility and unpredictability likely influenced profit-taking or broader concerns, leading to a decline in Baxter's stock value.
• Investor reactions to market conditions may have overshadowed the company-specific positive news, contributing to the stock's downward movement.

21.10.2025 - BAX Stock was up 5.2%

• The multiple class action lawsuits against Baxter International might have initially caused uncertainty and a dip in the stock price.
• However, investors might have regained confidence in the company due to positive developments or reassurances from Baxter International's management.
• This bullish movement could indicate that investors believe the impact of the lawsuits on the company's financials and reputation might be manageable.
• It's possible that some investors see an opportunity in the temporary dip caused by the lawsuits and are now buying the stock at a lower price, contributing to the bullish movement.

15.00.2026 - BAX Stock was up 5.2%

• Baxter International Inc. introduced its Dynamo Series smart stretcher, emphasizing technological innovation in acute care to improve patient safety and hospital workflow efficiency, likely boosting the positive stock movement.
• Despite a decrease in stake by Manning & Napier Advisors LLC, growing interest from other institutional investors and Baxter's focus on connected care solutions may have bolstered market confidence and contributed to the bullish trend.
• Initially trailing behind competitors, Baxter International Inc.'s stock performance saw a shift towards optimism with the launch of the Dynamo Series smart stretcher, influencing the bullish market movement.
• FDA clearance for Medtronic's smart insulin pen app, though unrelated to Baxter, indicates progress in healthcare technology, potentially benefiting companies like Baxter International Inc. through positive market effects.

12.10.2025 - BAX Stock was up 5.1%

• Despite the pending class action lawsuits and reminders to shareholders, Baxter International Inc. saw a bullish trend, indicating that investors may have confidence in the company's ability to navigate through legal challenges.
• The market movement could be attributed to positive developments within the company that outweigh the legal uncertainties highlighted in recent discussions.
• Investors might be optimistic about Baxter International's future performance and potential growth prospects in the healthcare industry, leading to increased buying activity and driving the stock price higher.

31.09.2025 - BAX Stock was down 5.4%

• Today's downward trend in Baxter International Inc. (BAX) stock may be linked to the following factors:
• A pending securities fraud class action lawsuit by The Gross Law Firm has caused apprehension among investors, resulting in a decrease in confidence and a sell-off of shares.
• Baxter has revised its annual outlook and lowered its 2025 guidance on multiple occasions, which might have negatively impacted investor sentiment, with the stock hitting a 52-week low after the latest adjustment in guidance.
• Despite Baxter's Q3 earnings surpassing expectations, the stock dropped due to a sales shortfall and a downward revision in the 2025 EPS forecast, suggesting potential challenges in revenue generation ahead.
• Ongoing investigations and shareholder alerts by legal firms like Faruqi & Faruqi, LLP and Bernstein Liebhard LLP have contributed to the overall uncertainty surrounding the company, potentially influencing the bearish market movement.